ADPT (adaptivebiotech.com) יחס שווי שוק לשווי בספרים

The current market quotes for Adaptive Biotechnologies (ADPT) visualized below demonstrate the price action of an asset whose operations rely on the automation of immunity analysis via robotics and AI. The business is not subject to market cycles, depending only on the cost of borrowed funds and genetic discoveries. Meanwhile, pricing power is limited by the US insurance reimbursement system, and the key metric is 29.39.

As Adaptive Biotechnologies (ADPT) pivots toward break-even and the commercialization of T-Detect, the market capitalization trend relative to the balance sheet reflects market confidence in the company's tangible assets. The price-to-book ratio helps determine whether the future success of immunosequencing is overpriced or if the asset is undervalued, signaling either fundamental cheapness or hidden systemic business risks.